Nexalin Acquires Digital Health Platform for $1.3M to Strengthen HALO™ Clarity Ecosystem

Event summary

  • Nexalin Technology acquired PONM, Inc. for $1.3M in shares to secure ownership of the digital health platform supporting HALO™ Clarity and Nexalin NeuroCare™.
  • The acquisition includes an exclusive license to AI-integrated software features for remote patient monitoring, treatment compliance, and virtual clinic management.
  • PONM’s platform is already deployed at UCSD, supporting HALO™ headset usage tracking and clinical research workflows for Nexalin’s TBI/PTSD military study.
  • GreenLight Ventures becomes a meaningful equity holder in Nexalin, aligning around the long-term success of HALO™ Clarity and Nexalin NeuroCare™.
  • The transaction includes a strategic partnership providing Nexalin with continued access to GreenLight’s product, engineering, and regulatory capabilities.

The big picture

Nexalin’s acquisition of PONM underscores the growing importance of integrated device-plus-software models in neurostimulation. By securing control over the digital infrastructure that connects its HALO™ Clarity device, patients, and physicians, Nexalin aims to strengthen its regulatory strategy and commercial deployment. The deal aligns with broader industry trends toward AI-enabled remote monitoring and virtual clinic management, positioning Nexalin to potentially lead in non-invasive neurostimulation therapies.

What we're watching

Regulatory Strategy
How the acquisition strengthens Nexalin’s ability to execute through pivotal trial activities and planned FDA submission for HALO™ Clarity.
Execution Risk
Whether Nexalin can successfully integrate and scale the PONM platform to support future physician-supervised, at-home neurostimulation programs.
Market Dynamics
The pace at which Nexalin can commercialize HALO™ Clarity as an at-home, physician-supervised therapy following the acquisition.

Related topics

Acquisition